Pretax income is the income that a company earns before paying income taxes. Adaptive Biotechnologies's pretax income for the
three
months ended in Dec. 2024 was $-33.7 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-159.6 Mil.
Adaptive Biotechnologies's pretax margin was -71.04%.
During the past 8 years, Adaptive Biotechnologies's highest Pretax Margin was -80.65%. The lowest was -148.63%. And the median was -109.77%.
Adaptive Biotechnologies Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Adaptive Biotechnologies's Pre-Tax Income
For the Biotechnology subindustry, Adaptive Biotechnologies's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-159.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (NAS:ADPT) Pre-Tax Income Explanation
Adaptive Biotechnologies's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 8 years, Adaptive Biotechnologies's highest Pretax Margin was -80.65%. The lowest was -148.63%. And the median was -109.77%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Adaptive Biotechnologies's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADPT has been successfully added to your 